Julie Brogaard Larsen

Dr. Julie Brogaard Larsen

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2020 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
JKJulia Marie Krei
Julia Marie Krei
HMHolger Jon Møller
Holger Jon Møller
JLJulie Brogaard Larsen
Julie Brogaard Larsen
Introduction Hemophagocytic lymphohistiocytosis (HLH) is a life‐threatening, hyperinflammatory disorder, characterized by multiorgan failure, fever and cytopenias. The diagnosis of HLH and its subtype Macrophage Activation Syndrome (MAS) remains a challenge. Interleukin 18 (IL‐18) is emerging as a potential biomarker for HLH/MAS but is currently not a part of diagnostic criteria. This systematic review aimed to assess the potential role of IL‐18 in the diagnosis and monitoring of HLH and MAS. Methods This review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. PubMed and Embase were searched on January 30th 2020. Studies included all subtypes of HLH and a range of underlying disorders in both children and adults. Results A total of 14 studies were included. Generally, serum IL‐18 was elevated in both primary and secondary HLH (>1,000 pg/ml) compared with other inflammatory conditions and with healthy individuals, thus serum IL‐18 may be able to discriminate between HLH and other inflammatory conditions. Significantly increased IL‐18 (>10,000 pg/ml) was also consistently described in MAS compared with other subtypes of HLH. The ability of IL‐18 to distinguish MAS from systemic juvenile idiopathic arthritis (JIA) is less unambiguous, as IL‐18 levels >100,000 pg/ml was described in sJIA patients both with and without MAS. Conclusion IL‐18 may help differentiate between HLH subtypes and other inflammatory conditions. Since HLH and MAS are rare disorders, only few and relatively small studies exist on the subject. Larger, prospective multi‐center studies are called for to assess the diagnostic precision of IL‐18 for HLH and MAS.

Verified
Journal Article
Open access
PDF file
CHChristine Lodberg Hvas
Christine Lodberg Hvas
JLJulie Brogaard Larsen
Julie Brogaard Larsen
The fibrinolytic system is a key player in keeping the haemostatic balance, and changes in fibrinolytic capacity can lead to both bleeding-related and thrombosis-related disorders. Our knowledge of the fibrinolytic system has expanded immensely during the last 75 years. From the first successful use of thrombolysis in myocardial infarction in the 1960s, thrombolytic therapy is now widely implemented and has reformed treatment in vascular medicine, especially ischemic stroke, while antifibrinolytic agents are used routinely in the prevention and treatment of major bleeding worldwide. Despite this, this research field still holds unanswered questions. Accurate and timely laboratory diagnosis of disturbed fibrinolysis in the clinical setting remains a challenge. Furthermore, despite growing evidence that hypofibrinolysis plays a central role in, e.g., sepsis-related coagulopathy, coronary artery disease, and venous thromboembolism, there is currently no approved treatment of hypofibrinolysis in these settings. The present review provides an overview of the fibrinolytic system and history of its discovery; measurement methods; clinical relevance of the fibrinolytic system in diagnosis and treatment; and points to future directions for research.

18 July 2017 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
JLJulie Brogaard Larsen
Julie Brogaard Larsen
AHAnne-Mette Hvas
Anne-Mette Hvas
Excessive perioperative bleeding is associated with increased morbidity and mortality as well as increased economic costs. A range of whole blood laboratory tests for hemostatic monitoring has emerged, but their ability to predict perioperative bleeding is still debated. We conducted a systematic review of the existing literature assessing the ability of whole blood coagulation (thromboelastography [TEG]/thromboelastometry [ROTEM]/Sonoclot), platelet function tests, and standard plasma-based coagulation tests to predict bleeding in the perioperative setting. We searched PubMed and Embase, covering the period from 1966 to November 2016. In total, 99 original studies were included. The included studies assessed TEG/ROTEM/Sonoclot (n = 29), platelet function tests (n = 27), both test types (n = 8), and standard coagulation tests only (n = 18), and some (n = 17) investigated the predictive value of testing in patients receiving antithrombotic medication. In general, studies reported low positive predictive values for perioperative testing, whereas negative predictive values were high. The studies yielded moderate areas under receiver operator characteristics (ROC) curve (for the majority, 0.60–0.80). In conclusion, while useful in the diagnosis and management of patients with overt bleeding, whole blood coagulation and platelet function tests as well as standard coagulation tests demonstrated limited ability to predict perioperative bleeding in unselected patients. Therefore, we recommend that both whole blood and plasma-based coagulation tests are primarily used in case of bleeding and not for screening in unselected patients prior to surgery.

25 September 2020 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
JLJulie Brogaard Larsen
Julie Brogaard Larsen
AHAnne-Mette Hvas
Anne-Mette Hvas
Disturbance in the balance between fibrin formation and fibrinolysis can lead to either bleeding or thrombosis; however, our current routine coagulation assays are not sensitive to altered fibrinolysis. The clot formation and lysis assay is a dynamic plasma-based analysis that assesses the patient’s capacity for fibrin formation and fibrinolysis by adding an activator of coagulation as well as fibrinolysis to plasma and measuring ex vivo fibrin clot formation and breakdown over time. This assay provides detailed information on the fibrinolytic activity but is currently used for research only, as the assay is prone to inter-laboratory variation and as it demands experienced laboratory technicians as well as specialized personnel to validate and interpret the results. Here, we describe a protocol for the clot formation and lysis assay used at our research laboratory.

8 March 2018 in Platelets
Verified
Journal Article
Closed access
MLMathies Appel Laursen
Mathies Appel Laursen
JLJulie Brogaard Larsen
Julie Brogaard Larsen
AHAnne-Mette Hvas
Anne-Mette Hvas
Disseminated intravascular coagulation (DIC) has a well-examined pathophysiology, yet some essential elements remain undetermined. During DIC, platelets play an important role in the development of micro thrombosis, but changes in platelet function parameters and their association with development of DIC have not been established. The present systematic review investigated reported associations between platelet function (activation, aggregation, and adhesion) and DIC. We performed a literature search in Embase and PubMed, following the Preferred Reporting Items for Systematic and Meta-Analyses (PRISMA) guidelines. In total, 22 articles were included; 14 human studies, seven animal studies, and one with both human and animal subjects. Platelet activation markers were generally reported to be higher in both DIC patients and animals with DIC than healthy controls, and higher among patients with DIC than patients without DIC. Six human and six animal studies investigated platelet aggregation, which were overall reported to be lower in DIC than in non-DIC or in healthy controls in both human and animal studies. Platelet aggregation was deemed to be confounded by low platelet counts, which are known to affect platelet aggregation analyses even within the reference interval. In conclusion, platelet activation analyses showed promise in diagnosis of DIC, but semi-automatization and standardization are warranted before these can be implemented in daily clinical practice. Changes in platelet aggregation analyses during DIC remain inconclusive, and further studies including adjustment for low platelet count are needed to clarify the role of platelet aggregation in DIC.

9 December 2021 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
JLJulie Brogaard Larsen
Julie Brogaard Larsen
MAMathies Appel Aggerbeck
Mathies Appel Aggerbeck
AGAsger Granfeldt
Asger Granfeldt
MSMorten Schmidt
Morten Schmidt
AHAnne-Mette Hvas
Anne-Mette Hvas
KAKasper Adelborg
Kasper Adelborg
Background The diagnostic accuracy of the ISTH’s disseminated intravascular coagulation (DIC) score remains to be investigated in contemporary patient populations. Objective To examine the positive predictive value (PPV) of an ISTH DIC score ≥5 for identifying patients with overt DIC in a Danish hospital laboratory information system database. Materials and Methods A population-based cross-sectional validation study in the Central Denmark Region (2015-2018). Patients with a DIC score ≥5 were identified from the hospital laboratory information system database. Only patients with a potential underlying cause of DIC were included in the analyses. Cases were adjudicated by the authors as the gold standard for DIC diagnosis. The diagnosis of overt DIC was assigned on the basis of clinical signs of microthrombosis and/or bleeding and available laboratory records. PPVs with 95% confidence intervals (CIs) were computed. Results Medical records of 225 patients were included. The overall PPV for overt DIC was 68% (95% CI, 61-74) and for overt + subclinical DIC, 83% (95% CI, 77%-88%) and increased with higher scores from 47% (95% CI, 35-59) for DIC score 5 to 88 (95% CI, 79-94) for DIC score ≥7. PPV was higher among intensive care patients and patient with sepsis, low antithrombin activity, prolonged activated partial thromboplastin time, or high Sequential Organ Failure Assessment score. Conclusion The accuracy of ISTH DIC score ≥5 was moderate for overt DIC but increased with increasing scores and depended on the underlying cause of DIC. This new knowledge provides guidance to physicians and enables DIC research using laboratory-based data.